| Patent Number |
Title Of Patent |
Date Issued |
| 7226910 |
Treatment of female sexual dysfunction with vasoactive intestinal polypeptide agonists |
June 5, 2007 |
| Methods for treating female sexual dysfunction are provided. A pharmaceutical composition containing a vasoactive agent selected from vasoactive intestinal potypeptide (VIP) and VIP agonists is administered to the vagina and/or vulvar region of the individual undergoing treatment. Th |
| 7056890 |
Combination therapy for effecting weight loss and treating obesity |
June 6, 2006 |
| The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject e |
| 6946141 |
As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature |
September 20, 2005 |
| A method is provided for treatment of premature ejaculation by administration of an antidepressant drug selected from tricyclic antidepressants, tetracyclic antidepressants, MAO inhibitors, azaspirone antidepressants, and atypical non-SRI antidepressants. In a preferred embodiment, a |
| 6593369 |
Methods, compositions, and kits for enhancing female sexual desire and responsiveness |
July 15, 2003 |
| Topical application of a prostaglandin directly to the clitoris is effective for enhancing female sexual desire and responsiveness. |
| 6593313 |
Co-administration of a prostaglandin and an androgenic agent in the treatment of female sexual d |
July 15, 2003 |
| Methods and formulations for treating female sexual dysfunction are provided. A pharmaceutical composition formulated so as to contain a selected vasoactive agent is administered to the vagina, vulvar area or urethra of the individual undergoing treatment. Suitable vasoactive agents |
| 6548490 |
Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfun |
April 15, 2003 |
| A method is provided for treating erectile dysfunction in a mammalian male individual. The method involves the transmucosal administration of a phosphodiesterase inhibitor or a pharmaceutically acceptable salt, ester, amide or derivative thereof, within the context of an effective dosing |
| 6495154 |
On demand administration of clomipramine and salts thereof to treat premature ejaculation |
December 17, 2002 |
| A method is provided for delaying the onset of ejaculation in an individual. The method involves systemic and on demand administration to an individual of a pharmaceutical formulation containing an amount of an active agent selected from the group consisting of clomipramine and pharm |
| 6472434 |
Method for minimizing excess collagen deposition |
October 29, 2002 |
| Methods and formulations for minimizing excess collagen are provided. A pharmaceutical composition formulated so as to contain a selected vasoactive agent is administered to the vagina, vulvar area or urethra of the individual undergoing treatment. Suitable vasoactive agents are vaso |
| 6469016 |
Treatment of female sexual dysfunction using phosphodiesterase inhibitors |
October 22, 2002 |
| Methods and formulations for treating female sexual dysfunction are provided. A pharmaceutical composition formulated so as to contain a selected vasoactive agent is administered to the vagina, vulvar area or urethra of the individual undergoing treatment. Suitable vasoactive agents |
| 6403597 |
Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
June 11, 2002 |
| A method is provided for treatment of premature ejaculation by administration of a phosphodiesterase inhibitor, e.g., an inhibitor of a Type III, Type IV, or Type V phosphodiesterase. In a preferred embodiment, administration is on as "as needed" basis, i.e., the drug is administered |
| 6228864 |
Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation |
May 8, 2001 |
| A method is provided for delaying the onset of ejaculation in an individual. The method preferably involves administration of an antidepressant drug, a serotonin agonist or antagonist, an adrenergic agonist or antagonist, an adrenergic neurone blocker, or a derivative analog thereof, |
| 6156753 |
Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysf |
December 5, 2000 |
| A method is provided for treating erectile dysfunction, e.g., vasculogenic erectile dysfunction such as vasculogenic impotence. The method involves the administration of a Type III phosphodiesterase inhibitor or a pharmaceutically acceptable salt, ester, amide or derivative thereof, |
| 6127363 |
Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfu |
October 3, 2000 |
| A method is provided for treating erectile dysfunction, e.g., vasculogenic erectile dysfunction such as vasculogenic impotence. The method involves the administration of a Type IV phosphodiesterase inhibitor or a pharmaceutically acceptable salt, ester, amide or derivative thereof, w |
| 6113939 |
Pharmaceutical compositions for treating priapism and peyronie's syndrome |
September 5, 2000 |
| A composition for the treatment of impotence via delivery to the urethra comprises a vasoactive prostaglandin and a polyethylene glycol dispersant having sufficient viscosity to be retained without spillage from a urethra receivable insert. The composition can additionally contain an |
| 6093181 |
Treatment of erectile dysfunction |
July 25, 2000 |
| Erectile dysfunction, particularly impotence, priapism and Peyronie's disease is treated by the transurethral administration of a therapeutically effective agent. The agents are administered to the urethra by means of a penile insert (1) having a rapidly releasing coating (4) containing |
| 6037346 |
Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
March 14, 2000 |
| A method is provided for treating erectile dysfunction in a mammalian male individual. The method involves the local administration of a phosphodiesterase inhibitor or a pharmaceutically acceptable salt, ester, amide or derivative thereof within the context of an effective dosing reg |
| 5919474 |
Transurethral administration of vasoactive agents to treat peripheral vascular disease, related |
July 6, 1999 |
| A method for treating peripheral vascular disease (PVD), related vascular diseases, and vascular impotence associated with such diseases, is provided. The method involves transurethral administration of a pharmaceutical formulation containing a selected vasoactive agent within the co |
| 5910316 |
Use of nitric oxide-releasing agents to treat impotency |
June 8, 1999 |
| A method of treatment for impotency is provided. The method involves the administration of nitric oxide by a nitric oxide-releasing agent capable of providing a penile erection-inducing amount of nitric oxide to the corpus cavernosum of the penis of an impotent male animal. Also provided |
| 5773020 |
Treatment of erectile dysfunction |
June 30, 1998 |
| Erectile dysfunction, particularly impotence, priapism and Peyronie's disease is treated by the transurethral administration of a therapeutically effective agent. The agents are administered to the urethra by means of a penile insert (1) having a rapidly releasing coating (4) contain |
| 5769088 |
Process and kits for diagnosing erectile dysfunction, and related methods of treatment |
June 23, 1998 |
| A method for diagnosing vasculogenic erectile dysfunction, including vasculogenic impotence and Peyronie's syndrome, is provided. The method involves transurethral administration of a vasodilating agent to induce an erection, followed by hemodynamic evaluation using duplex ultrasonograph |
| 5482039 |
Process for diagnosing erectile dysfunction, and related methods of treatment |
January 9, 1996 |
| A method for diagnosing vasculogenic erectile dysfunction, including vasculogenic impotence and Peyronie's syndrome, is provided. The method involves transurethral administration of a vasodilating agent to induce an erection, followed by hemodynamic evaluation using duplex ultrasonograph |
| 5474535 |
Dosage and inserter for treatment of erectile dysfunction |
December 12, 1995 |
| Erectile dysfunction, particularly impotence, priapism and Peyronie's disease is treated by the transurethral administration of a therapeutically effective agent. The agents are administered to the urethra by means of a penile insert (40) having a shaft with a deformable distal end w |
